Drug intelligence / Profile preview

PSA-PAH1

Development stage: Unknown
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Administration: Intratumoral (as Per Trial Design)

Overview

PSA-PAH1 is an investigational, prostate-specific antigen (PSA)-activated prodrug designed for the treatment of locally recurrent prostate cancer. The drug is engineered to be activated by PSA, an enzyme overexpressed in prostate cancer tissue, thereby releasing its cytotoxic payload selectively within the tumor microenvironment. This targeted activation aims to minimize systemic toxicity and maximize antitumor efficacy. The primary indication explored in clinical trials has been locally recurrent prostate cancer following biochemical failure after prior therapy[1][3][4].

Other names: PSA-Activated PSA-PAH1

Targets

PSA (Puromycin-sensitive aminopeptidase)

Beyond the preview

Go deeper on PSA-PAH1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PSA-PAH1.

Explore the full profile